Management Team

Saurabh is passionate about valuation and corporate finance and his expertise lies in valuing early stage companies and products that has several uncertainties involved in the life cycle. Having worked with several young life sciences companies in the areas of finance, he provides a strong financial perspective to the strategic decisions taken by the Board and intends to position himself as a Value Integrator to the CEO to drive long term growth of the company. Besides, his areas of interest include Real Options and Decision trees framework that captures the management’s flexibility in the times of uncertainty. He is the founder of Farmantra, a life sciences corporate finance advisory firm and an Independent Expert at European Commission. He has worked in the USA and India before embarking on his entrepreneurial venture in Spain and has an MBA from ESADE Business School.

Kevin McAllister has worked in the pharmaceutical industry for over 30 years.  Kevin joined the preclinical Nervous System research department of Sandoz and held positions of increasing responsibility up to Executive Director in Neuroscience at Novartis Institutes for Biomedical Research. Following this, Kevin worked as Principal Medical Scientific Expert in the Neuroscience Clinical Development Franchise where he contributed to projects with both pre- and post-marketing approval.  Kevin is Managing Director of Neurenable GmbH, a company dedicated to enable Neuroscience drug discovery and development. Kevin holds a PhD from the University of Wales, UK, and an MBA from the International Institute for Management Development, Lausanne, Switzerland.

Dr. C. Scart has more than 25 years of in-depth experience in the development and life-cycle management of innovative medicinal products in multinational pharmaceutical companies such as Janssen Cilag, Glaxo Wellcome, Recordati and CSLBehring as Clinical Development physician and Medical Director. Then she joined small biotechs (Pharnext as CMO, and Bioprojet as Head of Clinical Development) leading multi-national clinical development programs from Phase I to Phase IV across a broad range of therapeutic areas (mainly in neurology and rare diseases) and providing support for regulatory filings and interactions with FDA, EMA, and national regulatory authorities.
Her Professional education as a Medical Doctor certified in Pediatrics also includes postgraduate Master’s degrees in Public Health (Pierre et Marie Curie Paris VI Medicine University), and in the Methodology of therapeutic evaluation (Lariboisière Paris VII Medicine University).

Dr. Insa has worked for more than 20 years in multinational pharmaceutical companies such as Parke-Davis (now Pfizer), UCB Pharma, Uriach Group (now Palau Pharma) and ISDIN (from Esteve Group), before establishing SOM Biotech. His experience is in drug development, from drug identification to commercialization, including clinical research and licensing. He was involved in the development of products like Quinapril, Tacrine, Cetirizin, Levetiracetam, Rupatadin, Dersalazine, Cimicoxib, Albaconazole, Gemfibrozil, Gabapentin, Piracetam, Levocetirizine, Nanocapsuled Cyclosporin, Disitertide, and others. He received his Medical training and his PhD in Clinical Neurology from the University of Alicante, Spain; an MBA from ESADE Business School in Barcelona and an Executive Education Program from IESE, Barcelona. He has also attended a couple of biotech leadership programs at Harvard Business School, Boston. His background includes more than 45 publications and papers, 7 chapters in books, 87 congress communications and 9 pharmaceutical patents.